Mabuchi, S., Altomare, D.A., Connolly, D.C., Klein-Szanto, A., Litwin, S., Hoelzle, M.K., Hensley, H.H., Hamilton, T.C., Testa, J.R. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. (in press).
Lee, H., Kim, D., Dan, H.C., Wu, E.L., Nicosia, S.V., Golemis, E.A., Liu, W., Coppola, D., Brem, S.S., Testa, J.R., Cheng, J.Q. Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol. Cell. Biol. 2007 Jan 8; [Epub ahead of print].
Altomare, D., Testa, J.R. Cytogenetic and molecular genetic changes in malignant mesothelioma. In: O’Byrne, K., Rusch, V.W. (eds.), Malignant Pleural Mesothelioma. Oxford, UK: Oxford University Press, 2006.
Lin, D.C.C., Quevedo, C., Brewer, N.E., Grimes. M.L., Testa, J.R., Miller, F.D., Kaplan, D.R. APPL1 associates with TrkA and GIPC1, and is required for NGF-mediated signal transduction. Mol. Cell. Biol. 26: 8928-8941, 2006.
Varsano, T., Dong, M.Q., Niesman, I., Gacula, H., Lou, X., Ma, T., Testa, J.R., Yates, J.R. III, Farquhar, M.G. GIPC binds TrkA and APPL on peripheral endosomes and regulates TrkA signaling during clathrin-mediated endocytosis. Mol. Cell. Biol. 26: 8942-8952, 2006.
Pei, J., Kruger, W.D., Testa, J.R. High resolution analysis of 9p loss in human cancer cells using SNP-based mapping arrays. Cancer Genet. Cytogenet. 170: 65-68, 2006.
Yang, H., Bocchetta, M., Kroczynska, B., Elmishad, A.G., Liu, Z., Bubici, C., Mossman, B.T., Pass, H.I., Testa, J.R., Franzoso, G., Carbone, M. TNF-α inhibits asbestos induced cytotoxicity via a NF-kB dependent pathway: a possible mechanism for asbestos induced oncogenesis. Proc. Natl. Acad. Sci. USA 103: 10397-10402, 2006.
Poulikakos, P.I., Xiao, G-H, Gallagher, R., Jablonski, S., Jhanwar, S.C., and Testa, J.R. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25: 5960-5968, 2006.
Altomare, D.A., You, H., Xiao, G.-H., Ramos-Nino, M.E., Skele, K.L., De Rienzo, A., Jhanwar, S.C., Mossman, B.T., Kane, A.B., Testa, J.R. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24: 6080-6089, 2005.
Yuan, Z., Kim, D., Kaneko, S., Sussman, M., Bokoch, G.M., Kruh, G.D., Nicosia, S.V., Testa, J.R., Cheng, J.Q. ArgBP2γ interacts with Akt and p21-activated kinase-1 and promotes cell survival. J. Biol. Chem. 280: 21483-21490, 2005.
Altomare, D.A., Vaslet, C.A., Skele, K.L., De Rienzo, A., Devarajan, K., Jhanwar, S.C., McClatchey, A.I., Kane, A.B., Testa, J.R. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 65: 8090-8095, 2005.
Altomare, D.A., Testa, J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464, 2005.
Bellacosa, A., Kumar, C., Di Cristofano, A., Testa, J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 94: 29-86, 2005.
Wang, H.Q., Altomare, D.A., Skele, K.S., Di Cristofano, A., Kuhajda, F.P., Testa, J.R. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24: 3574-3582, 2005.
Xiao, G.H., Gallagher, R., Shetler, J., Skele, K., Altomare, D., Pestell, R.G., Jhanwar, S., Testa, J.R. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol. Cell. Biol. 25(6): 2384-2394, 2005.
Altomare, D.A., Wang, H.Q., Skele, K.L., De Rienzo, A., Klein-Szanto, A.J., Godwin, A.K., Testa, J.R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor growth. Oncogene 23: 5853-5857, 2004.
Balsara, B.R., Pei, J., Mitsuuchi, Y., Klein-Szanto, A., Wang, H., Unger, M., Testa, J.R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059, 2004.
Hirokawa, Y, Tikoo, A., Huynh, J., Utermark, T., Hanemann, O., Giovannini, M., Xiao, G.-H., Testa, J.R., Wood, J., Maruta, H. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J. 10: 20-26, 2004.